LCM
CBPO

Laurion Capital Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Laurion Capital Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-40,000
Closed -$3.59M – 1176
2015
Q3 		$3.59M Hold
40,000
– – 0.04% 275
2015
Q2 		$4.61M Buy
+40,000
New +$4.2M 0.04% 312

Other funds holding CBPO

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capstone Investment Advisors
Capstone Investment Advisors New York $57.4B AUM 26.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.38% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Laurion Capital Management's CBPO Position: Q4 2020 in Review

Laurion Capital Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2020, closing a stake of 5,248 shares — an estimated $583K sold.

Laurion Capital Management first reported a position in CBPO in Q2 2014 and held it in 6 quarters. The position peaked at $1.53M in Q2 2015. 89 funds tracked by Wall St. Rank hold CBPO as of Q4 2020.

  • Laurion Capital Management reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2020 after selling out during the quarter.
  • Laurion Capital Management sold 5,248 China Biologic Products Holdings, Inc. shares in Q4 2020, an estimated $583K.
  • Laurion Capital Management first reported a position in China Biologic Products Holdings, Inc. in Q2 2014 and held it in 6 quarters.
  • Laurion Capital Management's China Biologic Products Holdings, Inc. position peaked at $1.53M in Q2 2015.
  • 89 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2020.

Based on Laurion Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.